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ABSTRACT
Background: Oesophagitis is characterised by basal cell
hyperplasia and activated eosinophils, which release
mediators including major basic protein (MBP). MBP and
its mimetic polyarginine activate the calcium sensing
receptor (CaSR) on oesophageal epithelium. Fibroblast
growth factor 9 (FGF9) is implicated in epithelial
homeostasis and proliferative response to injury, but has
not been characterised in the oesophagus.
Objective: To characterise FGF9 in oesophageal epithe-
lium and oesophagitis, as the result of MBP activation of
the CaSR.
Methods: Human oesophageal epithelial cells (HET-1A)
were used to compare affects of calcium, polyarginine
and MBP-peptide on FGF9. HET-1A were transfected with
interfering RNA (siRNA
CaSR). FGF9, FGF receptors 2 and 3,
bone morphogenetic protein (BMP)-2, BMP-4 and noggin
mRNA expression were detected by reverse transcriptase
polymerase chain reaction. FGF9 was measured from
HET-1A and from normal, gastro-oesophageal reflux and
eosinophilic oesophagitis (EoE) patient biopsies using
ELISA and immunohistochemistry. HET-1A proliferation
was studied using bromodeoxyuridine and MTT.
Results: FGF9 was secreted by HET-1A cells treated with
polyarginine and MBP-peptide, but not calcium. This
effect was abrogated by siRNA
CaSR. FGF9 receptor mRNA
was present. HET-1A cells proliferated following rhFGF9,
but not MBP-peptide treatment, and rhFGF9 altered
transcription of downstream proliferation-related genes
(noggin, BMP-2 and BMP-4). FGF9 was increased in
biopsies from patients with eosinophilic oesophagitis,
which correlated with basal hyperplasia.
Conclusion: Eosinophil-released MBP acts on the CaSR
to increase FGF9 in oesophageal epithelial cells, leading to
proliferation. Increased FGF9 is found in biopsies of EoE
patients and may play a role in the pathogenesis of
oesophagitis.
Oesophagitis is characterised by inflammation and
morphological changes to the epithelium including
basal zone hyperplasia and elongation of vascular
papillae. Until recently, gastro-oesophageal reflux
disease (GORD) has been the primary disease
associated with oesophageal mucosal inflamma-
tion. During the last decade an emerging body of
literature supports the appearance of a new disease
termed eosinophilic oesophagitis (EoE). A systema-
tic review of the literature was recently published
as a consensus statement, and EoE was defined by
15 or more intraepithelial eosinophils per high-
power field (HPF) in the oesophageal mucosa.
1 In
EoE, eosinophils degranulate, releasing inflamma-
tory mediators, the most abundant of which is
major basic protein (MBP).
23MBP was originally
defined as a cytotoxin.
4 More recent studies show
that MBP acts as a mediator of inflammation and
can alter the function of epithelium.
5–7 In addition,
biopsies from patients with EoE and murine
models of this disease demonstrate high levels of
eosinophilic inflammation and also marked basal
zone hyperplasia.
89The pathogenetic link between
these two histological findings is unknown. We
postulate that MBP released from eosinophils acts
on oesophageal epithelial cells to cause these
changes.
There is no known receptor for MBP.
Polyarginine is similar in structure and function
to the biologically active moiety of MBP and has
been used as a molecular mimic for MBP. Poly-L-
arginine is a ligand for the extracellular calcium
sensing receptor (CaSR),
10 a G-protein coupled
receptor, which is found on many cell types
throughout the body.
11 The CaSR has many
known ligands, including calcium, other polyvalent
cations, spermine and amyloid b-peptide.
11 We
have previously characterised the presence and
functional activity of the CaSR in the human
oesophageal epithelium and in the oesophageal
epithelial cell line HET-1A.
12 Since the actions of
MBP mimic polyarginine, we hypothesise that
MBP, released by eosinophils in oesophagitis, acts
as a CaSR ligand.
In order to study the effects of MBP in
oesophageal epithelium, synthetic peptides of the
active moiety of MBP are used. These synthetic
peptides of MBP have been shown to mimic the
actions of MBP.
13 Treatment of cultured cells with
synthetic peptides, such as an MBP-peptide, is a
suitable model for assessing alterations in gene
expression.
14 Array analysis of HET-1A cells treated
with Ca
2+ (2.5 mmol/l) or MBP-peptide (5 mmol/l)
demonstrated increased fibroblast growth factor 9
(FGF9) mRNA only after MBP-peptide stimulation
(supplemental material). FGF9 is a 26 kDa secreted
protein, which leads to epidermal proliferation and
wound healing in the skin of mice
15 and has a
paracrine role in toxic liver injury.
16 FGF9 acts on
its receptors (FGFR2 and 3) to activate intracellular
signal transduction cascades on target cells,
17 18
which affects the expression of downstream target
genes including members of the bone morphoge-
netic protein (BMP) family. The expression of
BMP-2, BMP-4 and noggin (the inducible antago-
nist of BMP-2) are known to affect proliferation
and cell survival as a result of FGF9 activation in
human tissue.
19 BMP-4 is a downstream target of
FGF and canonical Wnt signalling that can induce
proliferation.
20 We have shown that BMP-2 is a
CaSR-dependent factor important for barrier
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21 Decreasing BMP-2
expression may decrease apoptosis of oesophageal epithelial
cells. Noggin acts as an antagonist of BMP-2 and is known to
induce proliferation in colonic epithelial cells.
21 22 Since func-
tional CaSR is present on oesophageal epithelium, this suggests
that MBP-induced FGF9 participates in epithelial hyperplasia in
oesophagitis.
Eosinophil-derived products in oesophagitis lead to increased
FGF9 secretion by oesophageal epithelial cells. Alterations to the
oesophageal mucosa, including basal zone hyperplasia and
vascular papillae elongation, should correlate with FGF9 protein
concentrations in mucosal biopsies. In this study we demon-
strate induction of FGF9 mRNA and protein expression
following activation of the CaSR by MBP-peptide and
polyarginine but not calcium. FGF9 increases mRNA in HET-
1A cells for proliferative BMP signalling and leads to prolifera-
tion as measured by in vitro assays. Patients with EoE
have increased FGF9 in oesophageal mucosal biopsies, which
correlates positively with alterations in histology known to
occur with oesophagitis. These results suggest that FGF9 may
be a key growth factor in the pathophysiology of EoE.
MATERIALS AND METHODS
Cell culture
The HET-1A human oesophageal epithelial cell line was
obtained from ATCC (Manassas, Virginia, USA), and cultured
according to the original protocol.
23 Cells were passaged weekly
and studied between passages 39 and 45. Bronchial epithelial
growth media (BEGM) with 0.5 mmol/l calcium chloride was
used as control media. Poly-L-arginine (MW=5000–15 000;
Sigma–Aldrich, Oakville, Ontario, Canada) was added at a
concentration of 1.3 mmol/l. MBP-peptide (0.1, 0.5 and 5 mmol/
l) was synthesised as described below. Calcium (2.5 mmol/l)
and recombinant human FGF9 (rhFGF9, 20–40 ng/ml; Abcam,
Cambridge, Massachusetts, USA) were also used to treat to
HET-1A cells where indicated.
Human tissue biopsies
Grasp biopsies of the distal oesophagus were obtained from
patients undergoing endoscopy for evaluation of gastrointest-
inal symptoms. Biopsies were fixed in 10% formaldehyde and
embedded in paraffin for routine histopathology; adjacent
biopsies were homogenised for FGF9 measurement. Patient
samples with a basal zone (25% were considered normal.
Patients with a basal zone of .25% and/or elongated vascular
papillae and 0–14 eosinophils per high-power field (HPF, 640
objective) were considered to have gastro-oesophageal reflux
disease (GORD). Eosinophilic oesophagitis (EoE) was defined as
the presence of 15 or more eosinophils in the maximally affected
HPF, where GORD had been ruled out.
1 Basal hyperplasia .25%
was a feature seen in all EoE biopsies.
Measurement of fibroblast growth factor 9
Tissue biopsies from patients for FGF9 protein analysis was
homogenised in 600 ml of phosphate-buffered saline (PBS) and
then centrifuged for 20 min at 2000 g at 4uC and supernatants
were collected for enzyme-linked immunosorbent assay (ELISA)
and protein measurement. For cell culture experiments, HET-1A
cells were plated in equal density in 24-well plates and
supernatants were collected at 18 h following treatment.
Total protein concentration was determined by the Bradford
method and FGF9 levels were measured by ELISA (Ray BioTech,
Norcross, Georgia, USA) according to the manufacturer’s
instruction, with results expressed as pg of FGF9/ml/mg of
total protein.
Immunohistochemistry
Formalin-fixed, paraffin-embedded oesophageal mucosal biop-
sies sectioned at 5 mm were rehydrated and endogenous
peroxidase activity was quenched with 3% H2O2. Non-specific
binding was blocked by 30 min incubation with 5% goat serum/
0.02% azide/0.02% Tween-20 in PBS. Primary mouse anti-
human immunoglobulins were purchased from Santa Cruz
Biotechnology (anti-FGF9 and anti-FGFR3; Santa Cruz,
California, USA) and R&D Systems (anti-FGFR2; R&D
Systems, Minneapolis, Minnesota, USA). Slides were incubated
overnight with anti-FGF9 (1:50), anti-FGFR2 (1:20) or anti-
FGFR3 (1:50) or with normal mouse immunoglobulin G (IgG) as
a negative control. Slides were then treated with biotinylated
anti-mouse IgG secondary antibody and then horseradish
peroxidase–streptavidin complex each for 30 min (Santa Cruz
Figure 1 Fibroblast growth factor 9 (FGF9) is increased by major basic
protein (MBP)-peptide or polyarginine. (A) Reverse transcriptase
polymerase chain reaction (RT-PCR) of mRNA from human oesophageal
epithelial (HET-1A) cells. Increased FGF9 mRNA following 18 h
incubation in control media, 2.5 mmol/l calcium chloride, 1.3 mmol/l
polyarginine or 5 mmol/l MBP-peptide, with glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as an internal control and water substituted for
cDNA as a negative control. A representative image is shown (n=3).
(B) FGF9 protein detection by enzyme-linked immunosorbent assay.
FGF9 protein from HET-1A cell supernatants after 18 h of incubation in
control media, 2.5 mmol/l calcium chloride, 1.3 mmol/l polyarginine or
5 mmol/l MBP-peptide. Cells transfected with siRNA
CaSR (open bars) or
scrambled siRNA constructs (solid bars). n=3; NS, not significant;
*p,0.05. (C) Identification of mRNA for both biologically active FGF9
receptors, FGFR2 and FGFR3 (all isoforms), in HET-1A oesophageal
epithelial cells. Detected by RT-PCR, a representative image is shown
(n=3).
Oesophageal disease
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peroxidase complex (ABC) method with 3,39-diaminobenzidine
substrate, counterstained with haematoxylin and visualised
using a Nikon Eclipse TE-2000U microscope, a Nikon DXM
1200C digital camera (Nikon, Mississauga, Ontario, Canada)
and NIS-Elements BR 2.30 software.
Synthesis of biologically active major basic protein-peptide
A peptide consisting of amino acids 89–117 of MBP (H-Gly-Gly-
His-Cys-Val-Ala-Leu-Cys-Thr-Arg-Gly-Gly-Tyr-Trp-Arg-Arg-
Ala-His-Cys-Leu-Arg-Arg-Leu-Pro-Phe-Ile-Cys-Ser-Tyr-OH)
13
was synthesised by the Queen’s Protein Discovery and Function
Unit. This peptide was generated from 0.2 mmol/l 4-(29,49-
dimethoxyphenyl-fmoc-aminomethyl)-phenoxy resin from 9-
fluoroenylmethoxycarbonyl L-amino acid derivatives using an
ACT 350 automated multiple peptide synthesiser (Advanced
Chemtech, Louisville, Kentucky, USA).
Generation and transfection of short interfering RNA
A sequence matching the criteria to be a target of siRNA against
the CaSR gene, but against no other gene, was determined by
BLAST analysis. This sequence is located between nucleotides
371 and 390 in the CaSR gene (59-AACCTTGATGAGTTC
TGCAAC-39). Sense and antisense template DNA primers were
generated and siRNA was transcribed following the manufac-
turer’s protocol (Silencer siRNA Construction Kit; Ambion,
Austin, Texas, USA). A control siRNA construct, consisting of a
scrambled sequence of the same nucleotides, was also synthe-
sised. HET-1A cells were transfected with 750 pmol/l siRNA
CaSR
or scrambled siRNA using Superfect reagent (3 mg/ml;
QIAGEN, Valencia, California, USA). We have shown pre-
viously that transfection using siRNA
CaSR significantly reduces
the expression and functional activity of the CaSR in HET-1A
cells.
12 21
Reverse transcriptase polymerase chain reaction analysis
RNA was isolated from HET-1A cells using Trizol (Invitrogen,
Carlsbad, California, USA). Reverse transcription was per-
formed using the QIAGEN RT Kit (QIAGEN) and the
QiaQuick PCR Kit (QIAGEN) as previously described.
12
Primers with specific annealing temperatures and cycles
included: FGF9 (59-AAG GAC TGC GGC CTG ATG-39 and
59-TTT GCT TTA AGT TCA CTG CGA TG-39) at 59.0uC for
33 cycles; GAPDH (59-TTA GCA CCC CTG GCC AAG G-39
and 59-CTT ACT CCT TGG AGG CCA TG-39) at 55.0uC for 24
cycles; FGFR2 (59-AAC CTA GCT ACA CTG AGC AGG G-39
and 59-TTC TCC TCC TGG GGA AGA TT-39) at 60.5uC for 32
cycles; and FGFR3 (59-CGG AAA GTT CGT CGC TGG-39 and
59-TTA CTG GGC CCT GAG TCT GG-39) at 60.5uC for 32
cycles. Standard conditions for each PCR cycle were 94uC for
30 s, followed by specific primer annealing temperature for 60 s
and 72uC for 30 s. Reverse transcriptase polymerase chain
reaction (RT-PCR) using BMP-2, BMP-4 and noggin primers and
conditions was performed as we have previously described.
21
Cellular proliferation assays
Proliferation assays were performed using the CellTiter 96 Non-
Radioactive Cell Proliferation Assay Kit (Promega, Madison,
Wisconsin, USA) and the BrdU Cellular Proliferation Assay Kit
(Roche, Laval, Quebec, Canada) following the manufacturer’s
Figure 2 (A) Treatment of human oesophageal epithelial (HET-1A) cells for 40 h with 20 or 40 ng/ml recombinant human fibroblast growth factor
(rhFGF9) results in decreased bone morphogenetic protein-2 (BMP-2) mRNA and increased mRNA for noggin and BMP-4. Cells were analysed by
reverse transcriptase polymerase chain reaction. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control and water as a
negative control. A representative image of one of three separate experiments is shown. (B) Bromodeoxyuridine (BrdU) assay. HET-1A cells incubated
with rhFGF9 (20 ng/ml) supplemented media (solid bars) show an increase in proliferation compared with cells grown in control media (open bars), at
24 h. n=3, *p,0.05. (C) MTT assay. Proliferation of HET-1A cells in control media (open bars) and cells in rhFGF9 (20 ng/ml) supplemented media
(solid bars). An increase in proliferation with FGF9 was detected at 48 h. n=3,*p,0.05. (MTT is 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide.)
Oesophageal disease
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4 cells/
ml. After 48 h, culture media was removed and replaced with
control media (BEGM) or media supplemented with 20 or
40 mg/ml recombinant human FGF9 (rhFGF9; Abcam), 0.1, 0.5
or 5 mmol/l MBP-peptide or 10% FCS and incubated for 24–48 h
as indicated. At each endpoint, the optical density of each
solution was measured at 570 nm and 450 nm for MTT
conversion and BrdU incorporation, respectively. (MTT is 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.)
Histopathology
Haematoxylin, phloxine and saffron (HPS)-stained 5 mm thick
sections of the formalin-fixed and paraffin-embedded oesopha-
geal mucosal biopsies were reviewed by a pathologist (DJH)
who was blinded to patient and clinical diagnosis. Biopsies of
patients were used when tissue was well-oriented and multiple
sections examined, with the most representative chosen for
analysis. Slides were assessed for the following histological
parameters:
c basal zone hyperplasia, defined as normal ((25%; 1), mild
(26–50%; 2), moderate (51–75%; 3) or severe (.75%; 4);
24
c degree of extension of vascular papillae of lamina propria
into squamous epithelium, defined as normal ((50%
epithelial thickness; 1) or elongated (.50%; 2);
1
c maximum intraepithelial eosinophil number per HPF (640
objective).
1
Tabulated scores represent the mean (with the standard
error) of seven patients in each group. Maximum eosinophils/
HPF is represented as the mean with the standard error (range
of eosinophils).
Statistics and calculations
Results are presented for quantitative experiments as the mean
of the number of experiments (n) with error bars representing
the standard error of the mean. Experimental results that are
visually represented are the result of three separate and
consistent experiments where one representative image is
shown. Statistical analysis was performed using Graphpad
Prism software V5.0. Significance (p,0.05) for quantitative data
was calculated using an unpaired, two-tailed Student t test for
two-group comparison and a one-way analysis of variance
(ANOVA) was used to compare experiments containing more
than two groups. For comparison of data from patient biopsies a
non-parametric Kruskal–Wallis test followed by a Dunn’s
multiple comparison test was used to determine significance.
RESULTS
Effect of major basic protein peptide and polyarginine on CaSR-
mediated FGF9 transcript expression and secretion
RT-PCR was performed on cDNA from HET-1A oesophageal
epithelial cells incubated for 18 h in calcium (2.5 mmol/l),
polyarginine (1.3 mmol/l) or MBP-peptide (5 mmol/l). Bands
representing reverse transcribed FGF9 mRNA were observed at
the expected 197 bp length. Compared to control conditions,
expression of FGF9 mRNA was only slightly greater in cells
treated with calcium but much greater with polyarginine and
MBP-peptide treatment (fig 1A, n=3), with consistent expres-
sion of housekeeping gene GAPDH. Therefore, constitutive
FGF9 mRNA expression was increased by both polyarginine and
MBP-peptide.
HET-1A cells transiently transfected with short interfering
(si)RNA
CaSR or with scrambled sequence of siRNA
CaSR were
treated with control media, increased calcium (2.5 mmol/l),
polyarginine (1.3 mmol/l) or MBP-peptide (5 mmol/l) for 18 h
and ELISA was used to measure FGF9 secretion (fig 1B, n=3).
Low levels of FGF9 were secreted constitutively by HET-1A cells
and were not affected by siRNA
CaSR transfection. Control media
(0.1 mmol/l Ca
2+) and increased calcium (2.5 mmol/l) treat-
ment did not show significantly different FGF9 production
following transfection of siRNA
CaSR compared to scrambled
siRNA transfection. Treatment with polyarginine and MBP-
peptide increased FGF9 secretion from HET-1A cells.
Transfection with siRNA
CaSR abrogated the production of
FGF9 from polyarginine and MBP-peptide treated cells com-
pared with scrambled siRNA transfected cells demonstrating
that this is a CaSR-dependent process.
FGF receptor 2 and 3 mRNA expression in HET-1A cells
To investigate the possibility that FGF9 can act in an autocrine
manner through FGF receptors on HET-1A cells, RT-PCR of
isolated mRNA identified FGF receptor isoforms 2 and 3. A
transcript for both FGFR2 and 3 was detected at the expected
lengths of 154 bp and 150 bp, respectively (fig 1C, n=3).
FGF9 alters transcription of BMP genes
Transcript isolated from HET-1A cells treated for 40 h in
control media or media supplemented with 20 or 40 ng/ml
recombinant human (rh)FGF9 protein was analysed by RT-PCR
and gel electrophoresis. Increased rhFGF9 induced a concentra-
tion dependent decrease in BMP-2 transcripts and increase in
both noggin and BMP-4 mRNA expression. The experiment was
Figure 3 Proliferation of human oesophageal epithelial (HET-1) cells as
determined by bromodeoxyuridine (BrdU) at 24 and 48 h. Cells were
cultured in control media or media supplemented with major basic
protein (MBP)-peptide (0.1, 0.5 or 5 mmol/l) or 10% fetal calf serum
(FCS). FCS acted as a positive control, no significant MBP-peptide
induced proliferation was observed (n=3).
Oesophageal disease
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Diagnosis Age (years) Sex Symptom Atopy Endoscopy
Maximal
eosinophils/high-
power field Medication
Normal
1 16 F Vomiting No Normal 0 None
2 2 M Feeding aversion Asthma Normal 0 Inhaled steroids*
3 11 F Pain, vomiting No Normal 0 None
4 14 M Pain, vomiting No Normal 0 Proton pump inhibitor
5 10 F Pain, vomiting No Normal 0 None
6 16 F Pain, vomiting Asthma Friability 0 Proton pump inhibitor
7 4 M Pain, vomiting Asthma Normal 0 None
Gastro-oesophageal
reflux disease
1 16 F Pain No Normal 2 None
2 14 M Pain No Furrowing, nodularity 9 Proton pump inhibitor
3 17 F Pain No Normal 0 Proton pump inhibitor
4 14 M Diarrhoea, vomiting Asthma, food
allergies
Furrowing, concentric
rings
0 Inhaled steroids*
5 9 F Vomiting No Erosions 0 Metoclopramide
6 14 F Pain, vomiting Asthma Normal 0 Proton pump inhibitor
7 6 F Diarrhoea, vomiting No Normal 0 Metoclopramide
Eosinophilic
oesophagitis
1 13 F Dysphagia No Furrowing, concentric
rings
271 None
2 4 M Dysphagia Asthma, food
allergies
Furrowing 160 Inhaled steroids*
3 8 M Pain No Furrowing, papules 18 None
4 16 M Dysphagia Asthma,
environmental
allergies
Furrowing, concentric
rings
63 Cetirizine
5 8 M Dysphagia Allergic rhinitis Furrowing, friability 114 None
6 11 F Dysphagia Asthma, food
allergy
Papules 169 Proton pump inhibitor,
inhaled steroids*
7 4 M Vomiting Food allergy Furrowing 234 None
*For asthma.
Figure 4 Localisation of fibroblast growth factor 9 (FGF9) and FGF receptors 2 and 3 by immunohistochemistry in histologically normal, gastro-
oesophageal reflux disease (GORD) and eosinophilic oesophagitis (EoE) oesophageal mucosal biopsies. Negative control (left side panels) mouse
immunoglobulin G (IgG) substituted for primary antibody. Brown colour indicates positive staining for all primary antibodies. FGF9 and receptor
immunostaining was increased in oesophagitis and was most pronounced in EoE (n=3; magnification, 6400).
Oesophageal disease
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fig 2A.
FGF9, but not MBP-peptide, stimulates HET-1A cell proliferation
BrdU and MTT assays were performed on subconfluent HET-
1A cells in the presence and absence of rhFGF9 (20 ng/ml). BrdU
incorporation in rhFGF9 treated cells was significantly increased
at 24 h (p,0.05) indicating proliferation, as shown in fig 2B
(n=3). The same experimental conditions were analysed by
MTT assay; after 48 h of rhFGF9 treatment the presence of
MTT significantly increased (p,0.05, n=3; fig 2C).
BrdU incorporation was analysed following treatment of
HET-1A cells with 0.1, 0.5 and 5 mmol/l MBP-peptide for 24 or
48 h. BEGM supplemented with 10% FCS was used as a positive
control for proliferation. Proliferation of HET-1A cells was not
significantly altered at either time by the addition to MBP-
peptide to culture medium (n=3; fig 3A,B).
Patients
The present study includes 21 paediatric patients who under-
went upper endoscopy for a variety of symptoms. Three groups
were distinguished by histopathology: normal oesophagus
(n=7), GORD (n=7) or EoE (n=7), with an average age of
10.4, 12.9 and 9.1 years, respectively (table 1). Five of seven
patients with EoE (71.4%) were male. One normal patient was
described as having friability, but no inflammation was seen on
biopsy. Endoscopy of patients with GORD was normal,
appearing in four cases (57.1%), and few eosinophils, other
inflammatory cells or basal change was seen. Only patients with
EoE presented with symptoms of dysphagia. All EoE patients
had abnormal endoscopic features (most commonly linear
furrowing in six patients) and biopsies containing >15
eosinophils/HPF and basal zone hyperplasia.
FGF9 is associated with eosinophilic oesophagitis
FGF9, FGFR2 and FGFR3 were localised using immunohisto-
chemistry (n=3, fig 4). Expression of FGF9 was observed in
biopsies from patients with GORD and to a greater extent EoE,
compared to normal control biopsies. Staining for FGF receptor
2 (FGFR2), the major epithelial FGFR, was observed throughout
the epithelium in biopsies from patients with GORD and EoE;
FGFR3 staining appears less prominent. In patients with EoE,
epithelial cells residing in the most basal layers of the epithelium
and those immediately adjacent to vascular papillae have the
strongest staining for FGF9 although staining is seen in
epithelial cells throughout the epithelium.
Histopathological assessment of biopsies is summarised in
table 2, with data presented as mean with the standard error.
No evidence of inflammatory characteristics (increased intrae-
pithelial inflammatory cells, basal zone .25% or elongated
vascular papillae) were found in any samples from normal
patients (n=7). Patients with GORD (n=7) had basal zone
hyperplasia (.25%) or elongated vascular papillae and small
numbers of eosinophils or other inflammatory cells in the
epithelium. Most patients with EoE (n=7) had marked
eosinophilic inflammation and basal zone changes (table 2).
Biopsies from patients with EoE (n=7) had significantly
increased basal zone changes, elongated vascular papillae and
intraepithelial eosinophils, compared to normal patients
(p,0.001). ELISA of supernatants from homogenised oesopha-
geal mucosal biopsies, expressed per mg total protein, showed
constitutive FGF9 protein with similar levels from normal and
GORD patient biopsies and increased FGF9 from EoE patient
biopsies (fig 5). FGF9 concentration in biopsies from patients
with EoE correlated positively with basal zone hyperplasia (fig 6,
r=0.51).
DISCUSSION
Eosinophilic oesophagitis is an emerging disorder, the cause of
which is unclear. Basal hyperplasia is a common feature of
oesophagitis and is particularly marked in biopsies from patients
with EoE. Our results indicate that a synthetic MBP-peptide and
polyarginine activate the CaSR on HET-1A cells, leading to
increased FGF9 production. FGF9 causes HET-1A cellular
proliferation and increased FGF9 is seen in biopsies of patients
with EoE. Evidence of receptors for FGF9 suggests an autocrine
action on oesophageal epithelial cells leading to proliferation.
We have previously reported the presence of functional CaSR
on HET-1A and that downregulation of the CaSR with
siRNA (siRNA
CaSR) transfection inhibited Ca
2+-stimulated
pERK, IL-8 secretion and intracellular Ca
2+ mobilisation in
HET-1A cells.
12 Ca
2+-stimulated BMP-2 production from colonic
Table 2 Assessment of inflammatory characteristics and fibroblast growth factor 9 (FGF9) concentration by diagnosis
Group
Maximum eosinophils/high-power field
Basal zone hyperplasia
score*
Vascular papillae
score*
FGF9 concentration (pg/ml/mg
protein)* Number* Range
Normal 0 (0) 0 1 (0) 1 (0) 414.1 (89.0)
Gastro-
oesophageal
reflux disease
1.6 (1.4) 0–9 1.3 (0.2) 1.4 (0.2) 540.8 (173.0)
Eosinophilic
oesophagitis
147.0 (36.7) 18–271 3.4 (0.3) 2 (0) 1296.0 (344.0)
*Results are given as the mean (SE).
Figure 5 Fibroblast growth factor 9 (FGF9) protein in homogenates
from oesophageal mucosal biopsies of patients with a normal
oesophagus (triangles), gastro-oesophageal reflux disease (GORD,
squares) or eosinophilic oesophagitis (EoE, circles), as detected by
enzyme-linked immunosorbent assay (ELISA). Expressed as pg/ml of
FGF9 per mg total protein as determined by Bradford assay. For each
patient group, the horizontal line indicates the group average, *p,0.05.
Oesophageal disease
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21 and Ca
2+-stimulated Wnt5a secretion from
colon cancer cells
25 have all been inhibited by transfection with
siRNA
CaSR. Therefore, the current experiments show that
siRNA
CaSR abrogated polyarginine and MBP-peptide stimulation
of FGF9 secretion, consistent with the interpretation that MBP
acts through activation of the CaSR to stimulate FGF9 release.
Treatment of these cells with a biologically active MBP-
peptide
13 increased FGF9 secretion in a manner comparable
with addition of polyarginine.
26 Because both the MBP-peptide
and polyarginine increased FGF9 transcript and secretion, which
was sensitive to RNA interference directed against the CaSR,
our current results suggest that MBP may work as an agonist of
the CaSR. Other eosinophil granule proteins such as eosinophil
peroxidase, eosinophil cationic protein and eosinophil-derived
neurotoxin also contribute to the pathophysiology of this
disorder, but MBP was studied since it is the most abundant
eosinophil product,
23is well studied and mimics polyarginine, a
known CaSR agonist. It would be interesting to utilise this
model to investigate the effects of these other mediators on the
CaSR and on FGF9 mediated proliferation.
Increased extracellular calcium concentrations did not
increase FGF9 amplicons or stimulate FGF9 secretion from this
oesophageal epithelial cell line, while polyarginine and MBP-
peptide application did stimulate FGF9 release. We have used
agonists of the CaSR in this cell line and have observed a variety
of rapid and delayed biological events, which were abrogated by
transfection of siRNA
CaSR.
12 Therefore, the current results
suggest that MBP-peptide and polyarginine both activate the
CaSR in HET-1A cells in a manner different to that of
extracellular calcium. Other studies have shown that aromatic
amino acids, when working as agonists of the CaSR, stimulate
different signalling cascades to that of extracellular calcium.
27
Additional studies are required to understand the mechanism of
differential signalling of MBP and other agonists through the
CaSR.
Regulation of proliferation in oesophageal epithelium is
unknown. Genes related to the transforming growth factor b
(TGFb) superfamily, including bone morphogenetic proteins,
are known to have altered mRNA transcript levels in
proliferating cells.
28 The genes for BMP-2, BMP-4 and noggin
were examined since their level of expression is related to FGF9
activation,
19 and proliferation in the gastrointestinal tract
involving the CaSR.
21 Transcripts of BMP-4 and noggin, were
increased following FGF9 treatment. We postulate that FGF9
induces downstream signals promoting epithelial proliferation
in the oesophagus, as it is known to do in other tissues.
19 FGF9
also acts to downregulate the pro-apoptotic gene BMP-2, an
antagonist of noggin, which may also contribute to increased
epithelial cell number and hyperplasia during oesophageal
inflammation. In summary, FGF9 increases transcription of
genes that may affect cell number and the survivability of HET-
1A cells.
In other tissues FGF9 acts following injury to promote
mitogenic activity
16 and wound healing
15 in an autocrine and
paracrine fashion.
16 29 Evidence that FGF9 secretion could result
in autocrine activation leading to increased cell division in our
experimental model was shown by transcript of receptors for
FGF9 (fig 1C), altered transcript of downstream genes (fig 2A)
and by proliferation of HET-1A cells as measured by BrdU and
MTT assays (fig 2B,C). Increased BrdU incorporation in DNA is
detected first, at 24 h, as cells progress through the S phase of
the cell cycle;
30 and MTT conversion is detected next at 48 h as
a measure of metabolic activity related to the G2 and mitosis
phases of the cell cycle.
31 Proliferation was not observed at either
24 or 48 h after addition of MBP-peptide to HET-1A cells in
culture (fig 3) indicating that the increased presence of FGF9 is
due to an actual transcriptional phenomenon rather than an
increase in overall cell number. Our experiments demonstrate
that, in this model, only FGF9 induced proliferation of HET-1A
cells.
FGF9 was increased in human oesophageal mucosal biopsies
from patients with GORD and EoE. The most intense
immunostaining was seen in basal epithelial cells (fig 4) in
patients with EoE. FGF9 protein as detected by ELISA was
increased in oesophageal mucosal biopsies from patients with
GORD and EoE, with EoE reaching statistical significance
compared with FGF9 concentrations in normal subjects (fig 5).
These results, and evidence that MBP-peptide induces FGF9 in
HET-1A cells, imply that increased FGF9 production is due to
secreted MBP in active oesophagitis. The proliferative effects of
FGF9 may then contribute to basal zone hyperplasia, a
characteristic of oesophagitis. Basal zone hyperplasia correlated
Figure 6 Fibroblast growth factor 9 (FGF9) concentration correlates
positively with extent of basal zone hyperplasia (r=0.51) in patients
with eosinophilic oesophagitis (EoE). Basal zone hyperplasia (.25%)
compared to FGF9 concentration (pg/ml/mg protein) as determined by
enzyme-linked immunosorbent assay (ELISA), performed on separate
oesophageal mucosal biopsies taken from an adjacent level.
Figure 7 Schematic of proposed mechanism of calcium sensing
receptor (CaSR)-mediated, major basic protein (MBP)-induced secretion
of fibroblast growth factor 9 (FGF9) during oesophagitis. Constitutive
FGF9 secretion likely plays a homeostatic role in oesophageal epithelium
maintaining proliferation. During oesophagitis, activated eosinophils
infiltrating the epithelium release MBP, selectively activating the CaSR,
leading to increased FGF9 secretion. FGF9 subsequently has proliferative
effects on the epithelium by autocrine action.
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number of eosinophils per HPF. Observation under light
microscopy will detect intact eosinophils, whereas degranulated
eosinophils, which have released MBP, will be more difficult to
quantify. The variability in the FGF9 concentrations between
individual patients, particularly those with EoE, is likely due to
the varying amounts of soluble MBP present at different stages
in the progression of EoE. The natural history of EoE is not well
characterised and further studies are needed to understand the
time course of EoE. We speculate that increased FGF9 levels
would correlate closely with a stage of EoE following eosinophil
degranulation.
The above results suggest that, in EoE, activated eosinophils
release MBP, causing activation of the CaSR on the surface of
epithelial cells, which increases FGF9 production leading to
basal cell hyperplasia, a feature of oesophagitis (fig 7).
Therefore, autocrine and paracrine proliferative action of FGF9
in oesophageal inflammation may contribute to basal zone
hyperplasia, a characteristic of oesophageal injury.
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